Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

CSL Will Acquire Protein Firm Talecris

August 18, 2008 | A version of this story appeared in Volume 86, Issue 33

Australian firm CSL is acquiring Talecris Biotherapeutics in Research Triangle Park, N.C., for $3.1 billion in cash, including $1.2 billion in debt. The combined company will have annual sales of about $4.5 billion and rank among the world’s largest providers of blood plasma-derived protein therapeutics and vaccines. Talecris was formed in 2005 by Cerberus Capital Management and Ampersand Ventures, which had acquired the former Bayer Plasma business for $590 million. In 2004, CSL bought a similar business, Aventis Behring, from Aventis for about $825 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.